Evidence map›Paper›PMID 32125733›Full record

ArticleJournal of clinical laboratory analysis2020

Downregulation of serum exosomal miR-320d predicts poor prognosis in hepatocellular carcinoma.

Wenxiao Li, Xuemei Ding, Shaohong Wang, Li Xu, Tao Yin, Shuangxi Han, Jianli Geng, Wenbing Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenxiao LiDepartment of Hepatobiliary Surgery, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
Xuemei DingDepartment of Hepatobiliary Surgery, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
Shaohong WangDepartment of Hepatobiliary Surgery, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
Li XuDepartment of Hepatobiliary Surgery, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
Tao YinDepartment of Hepatobiliary Surgery, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
Shuangxi HanDepartment of Hepatobiliary Surgery, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
Jianli GengDepartment of Hepatobiliary Surgery, The Municipal Hospital of Weihai, Weihai, China.
Wenbing SunDepartment of Hepatobiliary Surgery, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0003-1319-0395

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicroRNAs (miRNAs) is a class of functional regulator of tumorigenesis of human cancer including hepatocellular carcinoma (HCC). However, the potential clinical significance of serum exosomal miR-320d in HCC has not been elucidated.

methodsReal-time reverse transcription PCR was used to detect the expression pattern of serum exosomal miR-320d in patients with HCC, and the correlation between the deregulation of serum exosomal miR-320d and the clinical outcome of HCC was explored. The biological function of exosomal miR-320d in HCC was also investigated.

resultsOur results showed that the expression levels of exosomal miR-320d were remarkably reduced in the serum samples of HCC patients and the culture medium of HCC cell lines compared with their respective controls. Serum exosomal miR-320d could differentiate the HCC patients from healthy controls with high accuracy. In addition, its level was remarkably increased in the HCC patients who had received surgical treatment. Moreover, reduced serum exosomal miR-320d was associated with advanced tumor stage, positive lymph node metastasis, and poorly differentiated tumors. HCC patients with lower serum exosomal miR-320d had shorter overall and disease-free survival. Low serum exosomal miR-320d was identified to be an independent unfavorable prognostic factor for HCC. Finally, overexpression of miR-320d inhibited the proliferation and invasion of HCC cells, and BMI1 was demonstrated to be a direct target of miR-320d.

conclusionTaken together, serum exosomal miR-320d could be a potential non-invasive biomarker for the diagnosis and prognosis of HCC.

Indexed as

AgedBiomarkers, TumorCarcinoma, HepatocellularCase-Control StudiesCell-Free Nucleic AcidsCell Line, TumorCell ProliferationDisease-Free SurvivalDown-RegulationExosomesFemaleGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMaleMicroRNAsBiomarkers, TumorCell-Free Nucleic AcidsMicroRNAsMIRN320 microRNA, humandiagnosishepatocellular carcinomamiR-320dprognosisserum exosome

Identifiers

PMID32125733
PMCPMC7307335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.